DX3-213B |
| Catalog No.GC49811 |
DX3-213B es un inhibidor del complejo I de la fosforilaciÓn oxidativa (OXPHOS) activo por vÍa oral muy potente (IC50 = 3,6 nM). DX3-213B afecta la generaciÓn de ATP (IC50 = 11 nM) y bloquea el crecimiento de células MIA PaCa-2 (GI50 = 11 nM). DX3-213B se utiliza para la investigaciÓn del cÁncer de pÁncreas.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2749555-66-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DX3-213B is an inhibitor of mitochondrial complex I, also known as NADH dehydrogenase (IC50 = 3.6 nM).1 It inhibits the proliferation of MiaPaCa-2 cells cultured in galactose- but not glucose-containing media (IC50s = 9.1 and >3,000 nM, respectively). DX3-213B (10 mg/kg) reduces tumor volume in a Panc02 murine pancreatic ductal adenocarcinoma model.
1.Xue, D., Xu, Y., Kyani, A., et al.Multiparameter optimization of oxidative phosphorylation inhibitors for the treatment of pancreatic cancerJ. Med. Chem.65(4)3404-3419(2022)
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *